AstraZeneca Submits Brilinta To FDA, But Review Could Be Lengthy
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
AstraZeneca's submission of its antiplatelet drug Brilinta (ticagrelor) to FDA, announced Nov. 19, was on time for the firm's projections. Now it has to wait and see if an on-time approval is in the cards